Positive early results for Canopus's statin/caffeine flu treatment
This article was originally published in Scrip
Canopus BioPharma has reported positive preclinical results with StatC, a combination of a statin and caffeine, in the prevention and treatment of H5N1, H1N1 and H3N2 flu infections. In research carried out in collaboration with the Sun Yat-sen University in Guangzhou, China, 50μg of the undisclosed statin compound and 200μg caffeine administered preventatively was found to inhibit lung viral replication and damage in a mouse model, the US firm said. It is now planning further animal testing and is seeking private and government development partners. Statins act to inhibit viral entry by interfering with cholesterol synthesis to reduce the number of cholesterol-rich attachment sites on cell membranes.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.